Scientific research agreement between Foro delle Arti Srl, TES Pharma Srl and Fondo XGEN Venture
Apr 10, 2024
News
What's going on at Tes Pharma
Laboratory 4.0 of a Biotech Company
Feb 21, 2023
TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis
Nov 8, 2022
Prof. Roberto Pellicciari Recipient of the EFMC Honorary Fellow Award.
Aug 18, 2021
Research and Development of NAD+ modulators for the Treatment of Hepato-Renal Dysfunction in COVID-19 Patients
Jul 15, 2021
Pharmacological Modulation of NAD+ Homeostasis as a Novel Approach for the Treatment of Acute Kidney Disease
May 4, 2020
Integrated Platform for Research and Development of Innovative Drugs for Oncological and Metabolic Diseases
Mar 22, 2018